Bvf Partners L. P/Il Buys 968,112 Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) Stock

Five Prime Therapeutics Inc (NASDAQ:FPRX) major shareholder Bvf Partners L. P/Il bought 968,112 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average price of $4.00 per share, with a total value of $3,872,448.00. The purchase was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of FPRX opened at $3.89 on Friday. The stock has a fifty day moving average price of $4.14 and a two-hundred day moving average price of $6.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87. Five Prime Therapeutics Inc has a 52-week low of $3.22 and a 52-week high of $13.97. The company has a market cap of $151.17 million, a price-to-earnings ratio of -0.94 and a beta of 2.55.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.08). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The business had revenue of $2.98 million during the quarter, compared to the consensus estimate of $4.33 million. As a group, research analysts predict that Five Prime Therapeutics Inc will post -3.91 EPS for the current fiscal year.

Several research firms recently commented on FPRX. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 6th. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a research report on Thursday. ValuEngine upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Guggenheim downgraded Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $14.40.

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its position in Five Prime Therapeutics by 1,691.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,374 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 5,074 shares during the last quarter. Alambic Investment Management L.P. acquired a new stake in shares of Five Prime Therapeutics in the 2nd quarter valued at $69,000. Bailard Inc. increased its stake in shares of Five Prime Therapeutics by 23.8% in the 2nd quarter. Bailard Inc. now owns 13,000 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 2,500 shares during the period. Athanor Capital LP acquired a new stake in shares of Five Prime Therapeutics in the 2nd quarter valued at $104,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Five Prime Therapeutics in the 2nd quarter valued at $119,000. Hedge funds and other institutional investors own 74.41% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.